Vishal Nirmiti
6/10Allotment odds show up once subscription numbers come in.
Milega? Check first.
See the GMP, subscription, your allotment odds and a scored prospectus before you bid.
Allotment odds show up once subscription numbers come in.
Allotment odds show up once subscription numbers come in.
Allotment odds show up once subscription numbers come in.
Allotment odds show up once subscription numbers come in.
Allotment odds show up once subscription numbers come in.
Allotment odds show up once subscription numbers come in.
No Mainboard IPOs announced yet
New issues show up here as soon as their dates are out.
What GMP predicted vs what happened
Six automated modules read every RHP/DRHP by the same rules. Five of them score on their own, and the sixth combines those into one verdict.
From the closing day, institutional (QIB) demand nudges the score by up to 1.5 points: a strong QIB book adds to it, and once bidding has closed, an undersubscribed one takes away. Hover a score to see the adjustment.
Revenue, profit, margins, leverage and key ratios across three fiscal years.
Every named risk in the prospectus, sorted and weighed, plus any pending litigation.
Growth history, management track record and standing against listed peers.
How adaptable the business is to demand shocks, input costs and new markets.
Issue size, market conditions and where this filing sits in the listing calendar.
Combines the 5 scores into one overall number, with a plain-English list of what looks good and what worries us.
IPO Analysis · 4 min read
Moneyview's ₹1,092 crore IPO opens 24 Sept 2026 at ₹32–34. GMP ₹14 hints at ~41% listing gain. Financials, strengths, risks and our 7.4/10 score.
Admin,
IPO Analysis · 4 min read
Anand Seamless's ₹25.52 crore SME IPO closes 24 Sept 2026. Fixed price ₹72, 1,600-share lot, GMP flat. Customer concentration, cash flow risks and our 4.8/10 score.
Admin,
IPO Analysis · 4 min read
Varmora Granito's ₹708 crore mainboard IPO closes 24 Sept 2026. Price band ₹140–148, lot of 101 shares, GMP flat. Strengths, risks and our 6.8/10 score.
Admin,
New analyses and GMP moves, sent straight to your inbox.